hVIVO plc Director's Dealings (3938Z)
December 14 2017 - 9:00AM
UK Regulatory
TIDMHVO
RNS Number : 3938Z
hVIVO plc
14 December 2017
For immediate release 2.00pm: 14 December 2017
HVIVO PLC
("hVIVO" or the "Company")
Director's Dealings
hVIVO plc (AIM: HVO), a specialty biopharma company with
discovery and clinical testing capabilities, announces that Dr
Trevor Phillips, Executive Chairman of the Company, today purchased
9,035 Ordinary Shares of 5 pence each in the Company ("Ordinary
Shares") at a price of 56.0 pence per share.
Following this transaction, Dr Phillips' total interest in the
Company is 9,035 Ordinary Shares, representing approximately 0.01%
of the Company's issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the persons discharging managerial
responsibilities/persons closely associated
--- -----------------------------------------------------
a) Name Dr Trevor Phillips
--- ----------------- ----------------------------------
2 Reason for the notification
--- -----------------------------------------------------
a) Position/ Executive Chairman
status
--- ----------------- ----------------------------------
b) Initial Initial Notification
notification/
Amendment
--- ----------------- ----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- -----------------------------------------------------
a) Name hVIVO plc
--- ----------------- ----------------------------------
b) Legal Entity N/A
Identifier
--- ----------------- ----------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -----------------------------------------------------
a) Description Ordinary shares of 5 pence each
of the
financial
instrument, GB00B6ZM0X53
type of
instrument
Identification
code
--- ----------------- ----------------------------------
b) Nature Acquisition of ordinary shares
of the
transaction
--- ----------------- ----------------------------------
c) Currency GBP
--- ----------------- ----------------------------------
d) Price(s) Director Price (p) Volume
and volume(s) ----------- ---------- -------
Dr Trevor
Phillips 56.0 9,035
----------- ---------- -------
--- -----------------
e) Aggregated
information
- Aggregated
volume
- Price 9,035
- Aggregated 56.0p
total
GBP5,059.60
--- ----------------- ----------------------------------
f) Date of 14 December 2017
the transaction
--- ----------------- ----------------------------------
g) Place of London Stock Exchange, AIM
the transaction
--- ----------------- ----------------------------------
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive
Officer)
Graham Yeatman (Chief Financial
& Business Officer)
Media Enquiries +1 919 710 9658
Susan Flood (Head of Marketing)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Michael Burke
(Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster
Mitchell (UK) +44 203 727 1000
John Capodanno / Evan Smith
(US) +1 212 850 5705
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with
discovery and clinical testing capabilities, is pioneering a
human-based analytical platform to accelerate drug discovery and
development in respiratory and infectious diseases. Leveraging
human disease models in flu, RSV and asthma exacerbation, the hVIVO
platform captures disease in motion, illuminating the entire
disease life cycle from healthy to sick and back to health. Based
in the UK, market leader hVIVO has conducted more than 50 clinical
studies, inoculated over 2500 volunteers and has three
first-in-class therapies currently in development with a growing
pre-clinical pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGGGMCPUPMGPC
(END) Dow Jones Newswires
December 14, 2017 09:00 ET (14:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2023 to Apr 2024